【摘要】 目的:观察外周血干细胞移植(PBSCT)治疗急性白血病和恶性实体瘤的临床疗效观察。方法:自1999年11月至2004年3月,用PBSCT治疗急性白血病和恶性实体瘤11例,其中:急性淋巴细胞白血病(ALL)1例;急性非淋巴细胞白血病(ANLL)3例;非霍奇金淋巴瘤(NHL)4例;霍奇金淋巴瘤(HD)1例;乳腺癌1例;恶性黑色素瘤1例。除1例异基因外周血干细胞移植患者采用重组人粒细胞集落刺激因子(rhGCSF,惠尔血)对供者进行动员外,其他患者均为自体外周血干细胞移植,动员方案为化疗+rhGCSF。经2次采集,获得MNC为(5.91±2.34)×108/kg,CD34+细胞为(14.05±6.65)×106/kg,CFUGM(4.80±2.80)×105/kg。预处理方案3例患者采用FTBI加化疗,8例患者采用高剂量化疗方案。结果:所有患者移植后均重建造血。外周血WBC于移植后(6±1)天降至0。PLT于(7±1)天降至30×109/L以下。WBC>1.0×109/L、中性粒细胞>0.5×109/L、PLT>50×109/L,分别为(11±2)天、(11±2)天、(13±3)天。3例患者于移植后1～12个月死于肝功能衰竭或病情复发,2例患者带瘤生存3～5个月,其余患者均无瘤存活3～46个月,疗效仍在近一步随访中。结论:PBSCT对急性白血病和恶性实体瘤是一种安全有效的治疗方法。更多还原

【Abstract】 Purpose:To evaluate the therapectic effects of peripheral blood stem cell transplantation （PBSCT） on the treatment of acute leukemia and malignant solid tumors. Methods:Eleven patients with acute leukemia and malignant solid tumors were treated by PBSCT from December 1999 to March 2004. One of them was ALL-L₂, 1ANLL-M₁, 1ANLL-M₃,1ANLL-M_5b, 4NHL,1HD,1breast cancer,1malignant melanoma. In one patient who received allogeneic PBSCT, the donor received rhG-CSF at a dose of 10ug/kg/d by subcutaneous injection for 5d for PBSCT mobilization. Other patients received autologous PBSCT （APBSCT） combined with chemotherapy regimen followed by rhG-CSF. PBSCT were collected in two phases for mononuclear cell （MNC） of （5.91±2.34）×10⁸/kg.,CD₃₄ ⁺ cell （14.05±6.65）×10⁶/kg.,and CFU-GM （（4.80）±2.80）×10⁵/kg. Three patients received FTBI+CTX±Ara-c,8 patients high-dose chemotherapy (CTX,Vp-16,Ara-c,DTIC,BCNU〕as conditioning regimen respectively. Results:All patients were grafted and hematopoietic reconstitution was rapid. （6±1） days after transplantation,WBC was 0×10⁹/L; （7±1） days after transplantation,PLT was below to <30×10⁹/L.The days of WBC recovery were （11±2） days up to >1.0×10⁹/L,ANC （11±2） days up to >0.5×10⁹/L and PLT （13±3） days up to >50×10⁹/L. Of the patients, 3 died of liver function exhaustion or disease relapse 1-12 months after transplantation , 2 are still alive with disease for 3-5 months , but others are still alive and disease-free for 3-64 months. Conclusions:PBSCT is a safe therapeutic option that can significantly improve in acute leukemia and malignant solid tumors.更多还原